ADARx Pharmaceuticals, Inc. (ADRX) stock
ADRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Last filing: 10-Q on Nov 12, 2026
$13.82−0.18 (-1.29%)
Close on Nov 17, 2026Market cap $1.48BP/E –Yield –
Earnings
ADARx Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
–
Not yet scheduled
Revenue, Q3 FY2026
$2.20M
EPS, Q3 FY2026
-$1.74
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of ADARx Pharmaceuticals's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q3 FY2026ended Sep 30, 2026 | Nov 12, 2026after the close | $2.20M | – | -$1.74 | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
ADARx Pharmaceuticals has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When ADARx Pharmaceuticals puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases ADARx Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
See a number that looks wrong?